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surgically diagnosed IPF (sIPF) is uncertain. We aimed to investigate
the prognosis of patients with clinically diagnosed IPF (cIPF) and sIPF.
In this retrospective observational study, the Korean Interstitial
Lung Disease Study Group conducted a national survey to evaluate
the clinical, physiological, radiological, and survival characteristics of
patients with IPF from January 1, 2003 to December 31, 2007. Patients
were recruited from 54 universities and teaching hospitals across the
Republic of Korea. IPF diagnoses were established according to the
2002 American Thoracic Society (ATS)/European Respiratory Society
criteria (ERS) guideline. A total of 1685 patients with IPF (1027 cIPF
and 658 sIPF) were enrolled.
Patients with sIPF were significantly younger, predominantly
female, and nonsmokers (all P< 0.001). sIPF group had significantly
better initial pulmonary function. The proportion of computed tom-
ography-based honeycomb findings of patients with cIPF was higher
than in those with sIPF (P< 0.001). A Kaplan-Meier analysis showed
that the sIPF group had a better prognosis (P¼ 0.001). A survival
analysis showed that age, pulmonary function parameters, pulmonary
oxygen tension, honeycombing change, and combined lung cancer had a
significant influence on patient prognosis. However, there was no
significant difference in prognosis between the cIPF and sIPF groups
after adjusting for GAP (gender, age, physiology) stage.
The patients with sIPF had better clinical features than those with
cIPF. However, after adjusting for GAP stage, the sIPF group showed
similar prognoses as the cIPF group. This study showed that after
adjusting for GAP stage, the prognosis of patients with IPF is the same
regardless of the diagnostic method used.
(Medicine 95(11):e3105)
Abbreviations: % pred = percentage of the predicted value, ABGA
= arterial blood gas analysis, DLCO = diffusing capacity of the lung
for carbon monoxide, FEV1 = forced expiratory volume, FVC =
forced vital capacity, GAP = gender age and 2 lung physiology
variables (FVC and DLCO), HRCT = high-resolution computed
tomography, ILD = interstitial lung disease, IPF = idiopathic
pulmonary fibrosis, PaCO2 = arterial carbon dioxide tension, PaO2
= arterial oxygen tension, PFT = pulmonary function test, TLC =
total lung capacity.
INTRODUCTION
diopathic pulmonary fibrosis (IPF) is the most common formitial pneumonias.1 IPF is defined as a
essive and chronic fibrosing interstitial
efinite cause. It occurs primarily in older
www.md-journal.com | 1
patients, especially in the sixth and seventh decades, and is
limited to the lungs.2,3 It is also associated with increasing
respiratory symptoms and irreversible respiratory failure.3
Although IPF could be diagnosed clinically in the absence
of a surgical lung biopsy, it was recognised as a distinct clinical
entity that was associated with the histologic pattern of usual
interstitial pneumonia (UIP).2,4 In the last few years, the
paradigm of diagnosis of IPF has gradually changed from a
situation in which biopsy was the criterion standard to a
complex situation in which the multidisciplinary approach
was necessary. Such approach encompasses clinical, radiologi-
cal, and pathologic data.2,5–7 However, surgical biopsy is still
needed for IPF diagnoses because there are cases that cannot be
diagnosed without the histologic pattern.
It is well known that the median survival of patients with
IPF is <3 years.8,9 To provide precise prognostic information
and timely treatment to these patients, many predictive models
have been investigated. Previous studies have shown that older
age at diagnosis, male sex, decreased pulmonary function, and
impaired exercise capacity predict a worse outcome in patients
with IPF.8–15 However, the prognosis of patients with IPF with
a nontypical computed tomography pattern, who were even-
tually diagnosed by surgical lung biopsy examination, was
largely unknown. In 2012, Ley et al16 reported a simple-to-
use GAP (gender, age, physiology) model for predicting IPF
mortality, which is a scoring and staging system like the one for
Lee et allung cancer. This novel model consists of 4 clinical variables:
gender (G), age (A), and 2 pulmonary physiology parameters (P,
FVC, and DLCO). Each variable was assigned 1 to 3 points and
FIGURE 1. Flow chart of inclusion and exclusion of patients in the study
of the total, 1685 patients were divided into clinically diagnosed IPF (cIP
interstitial pneumonia, BOOP¼bronchiolitis obliterans organizing
interstitial lung disease, LIP¼ lymphocytic interstitial pneumonia, NSIP
iolitis-associated interstitial lung disease.
2 | www.md-journal.comthen added for staging; stage I (0–3 points), stage II (4–5
points), and stage III (6–8 points). The purpose of this study is
to evaluate whether clinically diagnosed IPF (cIPF) and surgic-
ally diagnosed IPF (sIPF) have different characteristics.
Furthermore, we aimed to evaluate the role and effect of
surgical biopsy in predicting prognosis in conjunction with
the GAP staging system.
PATIENTS AND METHODS
Patient Selection
The Scientific Committee in the Korean Academy of
Tuberculosis and Respiratory Diseases, comprising 54 univer-
sities and teaching hospitals, contacted pulmonary specialists
(n¼ 82) to identify patients with IPF. Newly diagnosed adult
IPF (30 years) patients were enrolled between 2003 and 2007.
Patients with a defined connective tissue disease, left ventricular
failure, or a history of ingestion of a drug or an agent known to
cause pulmonary fibrosis were excluded from the study. In total,
2186 patients were initially registered. Of these patients, the
following other forms of idiopathic interstitial pneumonias
(n¼ 501) were also excluded in this study (Figure 1): acute
interstitial pneumonia (AIP), bronchiolitis obliterans organizing
pneumonia (BOOP), desquamative interstitial pneumonia
(DIP), lymphocytic interstitial pneumonia (LIP), nonspecific
interstitial pneumonia (NSIP), and respiratory bronchiolitis-
Medicine  Volume 95, Number 11, March 2016associated interstitial lung disease (RB-ILD). Consequently,
1685 IPF patients were enrolled in the current study. In these
study subjects, age, sex, diagnostic method, smoking status and
. A total of 2186 patients were registered at 54 centers in Korea and
F, n¼1027) or surgically diagnosed IPF (sIPF, n¼658). AIP¼ acute
pneumonia, DIP¼desquamative interstitial pneumonia, ILD¼
¼nonspecific interstitial pneumonia, RB-ILD¼ respiratory bronch-
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amount, pulmonary function test (PFT), high-resolution com-
puted tomography (HRCT) findings, co-morbidities, respiratory
symptoms, arterial blood gas analysis (ABGA), and survival
were investigated. Chest CT findings were interpreted by
specialized thoracic radiologists at each hospital. Greater than
10% of CT findings were recorded as positive. Hospital data-
bases were screened for diagnosis of IPF according to the 2002
ATS/ERS criteria2 and were recorded in a web-based registry
(www.ild.or.kr).
Diagnoses were confirmed at each hospital by a multi-
disciplinary team consisting of specialists in pulmonary medi-
cine, radiology, and pathology according to the patients’ dates
of birth. Additionally, the members of the Scientific Committee
reviewed all the cases regardless of their inclusion.
Diagnostic Criteria
According to the international consensus classification,2 a
surgical lung biopsy is required for the definitive diagnosis of
IPF. However, a diagnosis of IPF can be considered in the
absence of a surgical lung biopsy specimen if certain major and
minor criteria are met. In such cases, all 4 major criteria and at
least 3 of the 4 minor criteria must be satisfied.2 When a biopsy
specimen was not available, all the major criteria except the last
(transbronchial lung biopsy specimen or bronchoalveolar
[BAL] fluid sample showing no features to support an alterna-
tive diagnosis) applied optionally, and at least 3 of the 4 minor
criteria had to be fulfilled. For patients with a surgical biopsy
specimen showing UIP, only the major criteria were considered
relevant. Although a surgical lung biopsy is required for accu-
rate diagnosis, a patient who was too old and had a low lung
function was diagnosed clinically at the physician’s discretion
Medicine  Volume 95, Number 11, March 2016without undergoing a biopsy. Additionally, a patient who
refused to undergo the surgical lung biopsy was diagnosed
clinically.
TABLE 1. Baseline Characteristics of Patients With cIPF and sIPF
Characteristics Total IPF (n¼ 1685)





Non smoker 553 (36.4)
Former-smoker 563 (37.1)
Current-smoker 402 (26.5)
Smoking duration, y 36.3 12.7
Smoking amounts (PYrs) 36.5 21.1
GAP index 3.12 1.37
GAP stage
Stage I 760 (60.2)
Stage II 455 (36.1)





Data are presented as the mean standard deviation or frequency (%). cI
age, and 2 lung physiology variables (FVC and DLCO); PYrs¼ pack-years
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Statistical Analysis
The Student t test was used to compare continuous vari-
ables, whereas Pearson x2 test was used to compare categorical
variables. Patients were censored if they were still alive when
last contacted (censored at the last status date), or had received a
lung transplant (censored at the time of the transplant). Survival
time was calculated as the time since diagnosis.
The survival was estimated using the Kaplan–Meier
method models. The log-rank statistic was used to compare
survival among groups. The effect of each variable on the risk of
death after controlling for age, sex, and pulmonary function
(GAP predictive variables) was modelled using the Cox pro-
portional hazards regression.16
Unless otherwise noted, all tests were 2-sided and per-
formed at the 0.05 significance level. SPSS Version 20 (SPSS,
Chicago, IL) was used for all analyses.
Ethics Statement
This study protocol was reviewed and approved by the
Institutional Review Board of the Severance Hospital Ethics
Committee (IRB approval number: 4–2009–0372), which
deemed that informed consents were waived.
RESULTS
Demographic Characteristics
A total of 1685 patients with IPF (cIPF: 1027 and sIPF:
658) were enrolled in this study. The mean follow-up duration
was 17.7 15.7 months. The demographic characteristics of the
participants are presented in Table 1. The mean age of the
participants was 67.9 9.6 years and the mean age was higher
Prognosis of IPFin cIPF than in sIPF group (P< 0.001). The proportion of males
was higher in cIPF than in sIPF group (P< 0.001). Regarding
the smoking history, the duration and total amount of smoking
cIPF (n¼ 1027) sIPF (n¼ 658) P
71.1 8.6 62.8 8.8 <0.001
245 (23.9) 220 (33.4) <0.001
782 (76.1) 438 (66.6)
281 (30.7) 272 (45.1) <0.001
381 (41.6) 182 (30.2)
253 (27.7) 149 (24.7)
37.8 12.7 33.1 12.2 <0.001
38.7 21.5 32.5 19.9 <0.001
3.59 1.22 2.42 1.29 <0.001
<0.001
358 (47.0) 402 (80.4)
363 (47.6) 92 (18.4)
41 (5.4) 6 (1.2)
<0.001
340 (33.1) 342 (52.0)
271 (26.4) 144 (21.9)
416 (40.5) 172 (26.1)
PF¼ clinically diagnosed idiopathic pulmonary fibrosis; GAP¼ gender,
; sIPF¼ surgically diagnosed idiopathic pulmonary fibrosis.
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TABLE 2. Initial Physiologic and Radiologic Characteristics of Patients with cIPF and sIPF
Characteristics Total IPF (n¼ 1685) cIPF (n¼ 1027) sIPF (n¼ 658) P
Pulmonary function test
FVC, L 2.52 0.82 2.41 0.77 2.71 0.86 <0.001
FVC (%) 75.1 18.4 73.5 18.5 77.7 18.0 <0.001
FEV1, L 2.04 0.62 1.93 0.57 2.20 0.65 <0.001
FEV1 (%) 85.3 20.1 84.6 20.2 87.8 19.7 <0.001
TLC, L 4.23 1.20 4.15 1.13 4.33 1.29 0.024
TLC (%) 83.4 19.6 82.1 18.2 85.0 21.2 0.033
DLCO, absolute 10.75 4.75 9.30 4.18 12.92 4.72 <0.001
DLCO (%) 62.3 21.5 57.9 20.4 68.9 21.3 <0.001
Resting PaO2, mmHg 79.4 22.5 73.2 19.9 88.3 23.1 <0.001
Resting PaCO2, mmHg 37.4 7.6 36.4 8.5 38.7 5.9 <0.001
Radiologic findings
Honeycombing change 1225 (72.7) 779 (75.9) 446 (67.8) <0.001
Ground glass opacities 963 (57.2) 523 (50.9) 440 (66.9) <0.001
Nodular lesions 344 (20.4) 219 (21.3) 125 (19.0) 0.072
Data are presented as the mean standard deviation or frequency (%). cIPF¼ clinically diagnosed idiopathic pulmonary fibrosis, DLCO
, FE
iopa
Lee et al Medicine  Volume 95, Number 11, March 2016were different between the 2 groups (P< 0.001, respectively).
The proportion of nonsmokers was higher in the sIPF group
(P< 0.001). The GAP index was calculated in this study as Ley
et al16 suggested in 2012. The cIPF group showed significantly
higher GAP indices than those of sIPF group (P< 0.001).
Clinical Characteristics
Table 2 shows the initial pulmonary function, arterial
blood gas analysis (ABGA), and radiologic characteristics of
the participants. At presentation, the predicted forced vital
capacity (FVC [%]), predicted forced expiratory volume in 1
second (FEV1 [%]), and the predicted diffusion capacity of the
lungs for carbon monoxide (DLCO [%]) were better in the sIPF
patients (P< 0.001, respectively). Resting PaO2 and PaCO2 at
presentation were also significantly different between the 2
groups (P< 0.001, respectively). Honeycombing change
(72.7%) and ground glass opacities (57.2%) were present in
most patients, whereas nodular lesions were only present in
some patients (20.4%). Ground glass opacities (P< 0.001) were
(%)¼ diffusion capacity of the lung for carbon monoxide % predicted
(%)¼ forced vital capacity % predicted, sIPF¼ surgically diagnosed idmore frequently shown in patients with sIPF, whereas the
proportion of honeycombing changes was significantly higher
in cIPF group (P< 0.001).
TABLE 3. Initial Presenting Symptoms of cIPF and sIPF
Symptoms Total IPF (n¼ 1685)
Symptom duration at presentation, mo 10.9 20.4




Chest pain 104 (6.2)
Asymptom 81 (4.8)
Data are presented as the mean standard deviation or frequency (%). cIPF
diagnosed idiopathic pulmonary fibrosis.
4 | www.md-journal.comTable S1, http://links.lww.com/MD/A781 shows the
comorbidities of patients. Diabetes and hypertension are the
most common comorbidities in both groups. Diabetes, cardio-
vascular diseases, and chronic renal diseases are significantly
more frequent in cIPF than sIPF group.
Initial presenting symptoms at diagnosis are presented in
Table 3. The average symptom duration at presentation was
10.9 20.9 months. There was no difference between cIPF and
sIPF group. Dyspnea on exertion and cough were the most
common symptoms. The 2 groups did not differ with respect
to symptoms.
Clinical Factors Associated With Survival
The clinical factors associated with survival are shown in
Table 4 (univariate analysis), Table 5 (multivariate analysis),
Table S2, http://links.lww.com/MD/A781, and Figures 2 and 3.
In the Kaplan–Meier survival analysis, patients with cIPF
showed a significantly poor prognosis compared with those
with sIPF (Figure 2, P¼ 0.001). Increased age, lower FVC,
V1 (%)¼ forced expiratory volume in one second % predicted, FVC
thic pulmonary fibrosis, TLC (%)¼ total lung capacity % predicted.FEV1, TLC, DLCO, and PaO2, the presence of honeycombing
changes on radiological tests, and the presence of combined
lung cancer were associated with a poor prognosis in all patients
cIPF (n¼ 1027) sIPF (n¼ 658) P
10.1 19.3 12.2 22.1 0.108
724 (70.5) 435 (66.1) 0.058
627 (61.1) 391 (59.4) 0.505
357 (34.8) 207 (31.5) 0.161
23 (2.2) 14 (2.1) 0.878
64 (6.2) 40 (6.1) 0.899
47 (4.6) 34 (5.2) 0.580
¼ clinically diagnosed idiopathic pulmonary fibrosis; sIPF¼ surgically
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
(34.1%) were the most common causes of death (Table 6).
TABLE 4. Clinical Factors Associated With Survival in cIPF and sIPF (Univariate Analysis)
Total IPF Group (n¼ 1685) cIPF (n¼ 1027) sIPF (n¼ 658)
Variable HR 95% CI P HR 95% CI P HR 95% CI P
Age 1.021 1.010–1.031 <0.001 1.009 0.996–1.023 0.186 1.028 1.009–1.048 0.005
Sex, M/F 1.096 0.880–1.364 0.415 0.930 0.703–1.229 0.608 1.240 0.868–1.773 0.237
Smoking (PYrs) 0.999 0.993–1.005 0.672 0.997 0.990–1.005 0.484 0.997 0.985–1.009 0.597
Symptom duration, mo 0.997 0.990–1.004 0.367 0.993 0.984–1.003 0.152 1.002 0.993–1.011 0.687
Initial function
FVC (%) 0.981 0.975–0.987 <0.001 0.984 0.976–0.992 <0.001 0.977 0.967–0.987 <0.001
FEV1 (%) 0.990 0.985–0.995 <0.001 0.993 0.986–1.000 0.037 0.987 0.978–0.996 0.003
TLC (%) 0.982 0.974–0.991 <0.001 0.990 0.978–1.001 0.073 0.973 0.961–0.986 <0.001
DLCO (%) 0.986 0.981–0.992 <0.001 0.991 0.984–0.999 0.021 0.980 0.969–0.990 <0.001
PaO2, mmHg 0.981 0.975–0.987 <0.001 0.986 0.978–0.994 <0.001 0.982 0.971–0.993 0.001
Honeycombing change

1.325 1.031–0.702 0.028 1.270 0.928–1.739 0.135 1.345 0.885–2.045 0.165
Combined lung cancer 2.200 1.602–3.020 <0.001 2.050 1.323–3.176 0.001 2.573 1.617–4.093 <0.001

Honeycombing change was presented on initial radiologic test.CI¼ confidence interval, cIPF¼ clinically diagnosed idiopathic pulmonary
orc
diop
Medicine  Volume 95, Number 11, March 2016 Prognosis of IPFwith IPF on univariate analysis (Table 4). However, age was not
a significant factor in the cIPF group and the presence of
honeycombing change was not significant in either of the cIPF
or sIPF groups. Sex, smoking amount, and duration of the
symptoms were not significantly related to mortality.
In analyses using GAP stage, an advanced GAP stage–
except stage III in sIPF (P¼ 0.215, n¼ 6)—was associated with
a significantly poor prognosis in all subjects in both the cIPF
and sIPF groups (Table S2, http://links.lww.com/MD/A781 and
Figure 3). However, there was no significant difference between
the two groups after adjusting for GAP stage (Figure 4).
In a multivariate analysis, GAP stage was an independent
prognostic factor in both groups, but PaO2 and honeycombing
change were not (Table 5). Furthermore, combined lung cancer
was significantly associated a poor outcome in the total IPF
group and the group with cIPF (P¼ 0.002 and P¼ 0.014,
respectively), but not in the sIPF group (P¼ 0.124).
The treatment history of patients is demonstrated in Table
fibrosis, DLCO (%)¼ diffusion capacity of CO% predicted, FEV1 (%)¼ f
capacity % predicted, PYrs¼ pack-years, sIPF¼ surgically diagnosed iS3, http://links.lww.com/MD/A781. The proportion of patients
treated with an immunosuppressant was higher in the sIPF
than the cIPF. Only 1 patient with sIPF underwent lung
TABLE 5. Clinical Factors Associated With Survival in cIPF and sI
Total IPF Group (n¼ 1685)
Variable HR 95% CI P HR
GAP stage <0.001
Stage I 1.000 1.000
Stage II 2.209 1.604–3.041 <0.001 1.841
Stage III 2.888 1.578–5.285 0.001 2.062
PaO2, mmHg 0.997 0.988–1.005 0.411 0.999
Honeycombing change

1.138 0.765–1.694 0.524 1.005
Combined lung cancer 2.216 1.352–3.634 0.002 2.144
There were 6 patients with stage III in surgically diagnosed IPF. CI¼ confi
2 lung physiology variables (FVC and DLCO), sIPF¼ surgically diagnosed
Honeycombing change was presented on initial radiologic test.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.transplantation. Respiratory failure (45.1%) and infection
ed expiratory volume in one second % predicted, FVC (%)¼ forced vital
athic pulmonary fibrosis, TLC (%)¼ total lung capacity % predicted.The proportion of patients who experienced respiratory failure
was higher in the cIPF than in the sIPF (P¼ 0.035).
DISCUSSION
This study demonstrated that GAP staging was applicable
to both the sIPF and cIPF groups that had similar mortality
predictions according to GAP stage.
Since Ley et al16 reported the GAP index and staging
system in 2012, it has simply been used for predicting the
clinical course of patients. However, the original cohort
included patients diagnosed by both surgical and clinical
methods; therefore, the GAP model has never been stipulated
as applicable only to patients diagnosed by biopsy or clinically.
The results of the present study show that the predicted prog-
nosis of patients with sIPF is not different from those with cIPF
when using the GAP model.
The new 2011 ATS/ERS IPF diagnostic criteria have
reduced the importance of surgical lung biopsy; however,
PF (Multivariate Analysis)
cIPF (n¼ 1027) sIPF (n¼ 658)
95% CI P HR 95% CI P
0.005 <0.001
1.000
1.247–2.718 0.002 2.698 1.508–4.827 0.001
1.051–4.048 0.035 13.418 2.780–64.764 0.001
0.988–1.011 0.908 0.999 0.985–1.012 0.832
0.630–1.604 0.984 1.543 0.722–3.297 0.262
1.167–3.938 0.014 2.045 0.823–5.081 0.124
dence interval, cIPF¼ clinically diagnosed IPF, GAP¼ gender, age, and
IPF.
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FIGURE 2. Kaplan–Meier estimates of survival for patients with
Lee et alHRCT has become essential. As a result, physicians now more
frequently diagnose IPF without a lung biopsy.3 However, the
prognosis of patients with IPF who are diagnosed by surgery is
unknown. This study aimed to evaluate whether sIPF and cIPF
groups have different characteristics, as well as the predict-
IPF according to diagnostic method. cIPF¼ clinically diagnosed
idiopathic pulmonary fibrosis, sIPF¼ surgically diagnosed idio-
pathic pulmonary fibrosis.ability of the GAP staging system in patients with IPF who
eventually underwent surgical lung biopsy in comparison with
patients with cIPF. Although there may be sampling errors and
FIGURE 3. Survival analysis for total IPF patients according to GAP
stage with Cox proportional hazard model. GAP¼gender, age,
and 2 lung physiology variables (FVC and DLCO).
6 | www.md-journal.cominterobserver variations in the surgical lung biopsy procedure,
lung biopsy still plays an important role in diagnosing IPF,
especially when the HRCT and/or clinical features are uncertain
to make a diagnosis.17 Because of the different prognoses and
therapies, an accurate diagnosis among the interstitial lung
diseases is very important.18 It is also important to allow for
the investigation of potentially different mechanisms that may
be operative during the early, intermediate, and end stages of the
disease. This knowledge could lead to the implementation of
targeted therapeutic interventions during the early disease
stages.
Raghu et al19 reported that patients with new-onset IPF
could be diagnosed by a clinical or radiological expert’s assess-
ment; however, approximately one-third of patients with new-
onset IPF needed surgical lung biopsy for accurate diagnosis
despite an expert review of clinical-radiological features.
Additionally, another study demonstrated that 44 patients were
described as having possible nonspecific interstitial pneumonia
(NSIP) or definite NSIP by HRCT findings. Ultimately, 26
(59.1%) of those 44 patients were diagnosed with IPF, whereas
the remaining 18 patients (40.9%) were diagnosed with NSIP by
histopathology.20 Therefore, a lung biopsy may be required
when a diagnosis is uncertain, when less experienced clinicians
manage patients, and when the clinical diagnosis is not IPF.21
Similarly, previous studies22–25 have shown that HRCT
findings in 30% to 50% of patients with IPF are not typical for
the IPF criteria. Typical CT findings of IPF included the
following: subpleural, basal predominance; reticular abnorm-
ality; honeycombing with or without traction bronchiectasis;
and absence of features listed as inconsistent with the UIP
pattern. Consistent with the results of these studies, the pro-
portion of patients with sIPF was 39.1% in our study. Further-
more, the proportion of honeycombing findings was
significantly lower in the sIPF group (P< 0.001).
Generally, physicians are reluctant to diagnose IPF by
surgical lung biopsy if patients are clinically unsuitable for
surgery. As a result, patients with cIPF tend to be older and
male. Ley et al16 suggested male sex as one of the poor
prognostic factors. Patients with cIPF also had a more severe
smoking history, worse lung function results, relatively more
dominant honeycombing on HRCT, and more comorbidities.
This cIPF group tended to undergo conservative care rather than
aggressive treatment. In general, owing to the worse clinical
features among patients with cIPF, they showed a significantly
poorer prognosis than patients with sIPF in a Kaplan–Meier
survival analysis (P¼ 0.001). Although the patients had the
same diagnosis, the physician’s selection bias led to the differ-
ences in clinical features reported and the mortality in patients
with cIPF and sIPF. We expected that cIPF group would
demonstrate a relatively longer duration of symptoms and a
higher frequency of the following symptoms: dyspnea, cough,
sputum, hemoptysis, and chest pain. However, there was no
significant difference between the cIPF and sIPF groups regard-
ing symptoms. This may be one reason why the severity of IPF
varies according to the subjective perception of symptoms and
the healthcare provider’s awareness.3
Ley et al16 demonstrated the GAP index and staging
system for predicting mortality in mixed groups of clinically
and surgically diagnosed IPF. As in their study, our study
showed that an advanced GAP stage tended to be associated
with a significantly worse prognosis. Previous studies have
Medicine  Volume 95, Number 11, March 2016shown that patients with IPF who had discordant UIP (histo-
logical UIP pattern and nontypical CT pattern), which is usually
diagnosed surgically, had a better prognosis than in patients
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 4. Survival analysis for IPF group according to GAP stage: (A) GAP stage I (n¼760), (B) GAP stage II (n¼455), (C) GAP stage III
ros
CO)
Medicine  Volume 95, Number 11, March 2016 Prognosis of IPFwith IPF who had concordant UIP (histological UIP and typical
CT pattern), which is usually diagnosed clinically.20,25 How-
ever, these studies had insufficient sample sizes to compare
patient prognoses, and they did not consider individual clinical
conditions. Similar to previous studies, ours showed that
patients with sIPF had a better prognosis than those with cIPF,
as assessed by a Kaplan–Meier analysis. However, there were
no significant differences in mortality between patients with the
same GAP stage, regardless of the diagnostic method used.
Therefore, this study shows that the GAP model is applicable in
predicting the prognosis of both sIPF and cIPF groups.
Furthermore, our univariate analysis showed that PaO2 and
honeycomb findings on HRCT, and combined lung cancer
could be prognostic factors in patients with IPF (Table 4).
Previous studies have shown that hypoxemia and a quantitative
scoring system by HRCT could be useful in predicting the
prognosis of IPF patients.26–29 However, a multivariate analysis
revealed that PaO2 and honeycomb findings were not signifi-
cant in our study. These results might be explained by the fact
that we were unable to examine lung fibrosis scores and
emphysema grades in CT findings and did not evaluate phys-
iological function using test like 6-minute-walk distance
(6MWD).
This study has some limitations. First, we used a defi-
nition from the 2002 ATS/ERS guidelines, which were
updated in 2011. In the past, surgical lung biopsy had an
(n¼47). cIPF¼ clinically diagnosed idiopathic pulmonary fib
GAP¼gender, age, and 2 lung physiology variables (FVC and DL
with GAP stage III.important role in IPF diagnoses, whereas HRCT has an
essential role in the updated guideline. Additionally, effi-
cacy-proven drugs (pirfenidone or nintedanib) were not used
TABLE 6. Cause of Death in cIPF and sIPF
Causes of death Total IPF (n¼ 1685)
Respiratory failure 139 (45.1)
Infection 105 (34.1)
Heart failure 15 (4.9)




Data are presented as frequency (%). The cause of death was investigated in
sIPF¼ surgically diagnosed IPF.
Trauma or malignancy other than lung cancer.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.in the past. Although Ley et al16 also created the GAP model
using a derivation cohort and validation cohort that had been
diagnosed between 2000 and 2010, there may be some differ-
ences between this study population’s patients and those
diagnosed by the 2011 ATS/ERS guidelines. Second, the
duration of follow-up for this study’s population was relatively
short, with an expected median survival time of approximately
3 years in patients with IPF. However, this was an adequately
large, multicenter study for validating the GAP model and, in
the original article by Ley et al, the median follow-up time was
also not relatively long (1.7 years in the derivation cohort),
Third, chronic hypersensitivity pneumonitis is difficult to
distinguish from IPF. However, we tried to identify patients
with chronic hypersensitivity pneumonitis by history, clinical
presentation, and laboratory results. The Scientific Committee
of the Korean Academy of Tuberculosis and Respiratory
Diseases also reviewed the diagnoses. Finally, our study
had only 6 sIPF patients with a GAP stage of III, and the
prognosis survival analysis of this group was not significant.
This may be because we did not check the ‘‘cannot perform’’
category of DLCO.
In conclusion, patients with sIPF showed better clinical
features than patients with cIPF. Moreover, sIPF patients are
found to be younger and have favorable lung function when
compared with cIPF patients. The GAP model could be
applicable in the prediction of prognosis in both sIPF and cIPF
is, sIPF¼ surgically diagnosed idiopathic pulmonary fibrosis,
. There are only 6 patients in the surgically diagnosed IPF groupgroups. In addition, IPF patients might have the same prognosis
after adjusting for GAP stage regardless of the diagnostic
method used.
cIPF (n¼ 1027) sIPF (n¼ 658) P
104 (48.4) 35 (37.6) 0.035
66 (30.7) 39 (41.9) 0.056
12 (5.6) 3 (3.2) 0.566
17 (7.9) 11 (11.8) 0.272
16 (7.4) 5 (5.4) 0.704
308 of 415 deceased patients with IPF. cIPF¼ clinically diagnosed IPF,
www.md-journal.com | 7
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